摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-fluoro-8-(3-adamantyl-ureido)octanoate | 1168116-12-8

中文名称
——
中文别名
——
英文名称
ethyl 2-fluoro-8-(3-adamantyl-ureido)octanoate
英文别名
Ethyl 2-fluoro-8-(3-adamantylureido)octanoate;ethyl 8-(1-adamantylcarbamoylamino)-2-fluorooctanoate
ethyl 2-fluoro-8-(3-adamantyl-ureido)octanoate化学式
CAS
1168116-12-8
化学式
C21H35FN2O3
mdl
——
分子量
382.519
InChiKey
AMBNKCBEJAPCKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    27
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    67.4
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    ethyl (Z)-2-fluoro-8-(3-adamantyl-ureido)-oct-2-enoate 氢气甲醇 、 crude product 作用下, 以 甲醇 为溶剂, 反应 1.5h, 以to give ethyl 2-fluoro-8-(3-adamantylureido)octanoate (1.7 g, 93%) as a white solid的产率得到ethyl 2-fluoro-8-(3-adamantyl-ureido)octanoate
    参考文献:
    名称:
    USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES
    摘要:
    本文公开了治疗炎症性血管疾病的组合物和方法。炎症性血管疾病的例子包括但不限于支架内狭窄、冠状动脉疾病(CAD)、心绞痛、急性心肌梗死、急性冠状动脉综合症、慢性心力衰竭(CHF)、周围动脉闭塞性疾病(PAOD)、严重肢体缺血(CLI)、心脏、肾脏、肝脏和肠道缺血、肾功能衰竭、心肌肥大、动脉粥样硬化、腹主动脉瘤、血管炎、颈动脉狭窄等。
    公开号:
    US20100063583A1
点击查看最新优质反应信息

文献信息

  • USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS
    申请人:Webb Hsu Heather K.
    公开号:US20090270452A1
    公开(公告)日:2009-10-29
    Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.
    本文揭示了一种通过给予可溶性环氧化物水解酶抑制剂来增强受试者平滑肌功能的化合物、组合物和方法,并用于治疗患有平滑肌障碍的受试者,包括勃起功能障碍、膀胱过度活跃、子宫收缩和肠易激综合征。
  • [EN] SOLUBLE EPOXIDE HYDROLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ÉPOXYDE HYDROLASE SOLUBLE
    申请人:ARETE THERAPEUTICS INC
    公开号:WO2009086429A1
    公开(公告)日:2009-07-09
    Disclosed are amide and urea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.
    揭示了一种抑制可溶性环氧水解酶(sEH)的酰胺和脲类化合物和组合物,以及制备这些化合物和组合物的方法,以及使用这些化合物和组合物治疗患者的方法。这些化合物、组合物和方法可用于治疗各种由sEH介导的疾病,包括高血压、心血管、炎症和糖尿病相关疾病。
  • SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
    申请人:Aavula Bhasker R.
    公开号:US20090247521A1
    公开(公告)日:2009-10-01
    The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.
  • [EN] SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION<br/>[FR] INHIBITEURS SOLUBLES DE L'ÉPOXYDE HYDROLASE POUR LE TRAITEMENT DE DYSFONCTIONNEMENT ENDOTHÉLIAL
    申请人:ARETE THERAPEUTICS INC
    公开号:WO2009086426A2
    公开(公告)日:2009-07-09
    The present invention generally relates to a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for use in treating and ameliorating the symptoms of diseases related to endothelial dysfunction.
  • [EN] USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS<br/>[FR] UTILISATION D'INHIBITEURS DE L'ÉPOXYDE HYDROLASE SOLUBLE DANS LE TRAITEMENT DE TROUBLES DU MUSCLE LISSE
    申请人:ARETE THERAPEUTICS INC
    公开号:WO2009129501A1
    公开(公告)日:2009-10-22
    Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.
查看更多